Basel Shoua
@Baselsho
Hematologist/Oncologist, TMC Cancer Center
قد يعجبك
In 2025, many important and long-awaited studies were published. I included them but kept the algorithms unchanged, as there are open questions about how these data will impact practice, particularly in early and metastatic HER2+ disease and mTNBC. @DFCI_BreastOnc #SABCS25
🚨 ONCO EMERGENCY: How to Manage EXTRAVASATION in 30 Seconds 🩺💉 Extravasation of chemotherapy = oncology emergency. Early recognition + immediate action = tissue saved. Here’s the crisp, protocol-ready approach 👇 1️⃣ STOP Immediately ❌ Stop infusion ❌ Do not flush ✔️ Leave…
Given the emerging data of MajesTEC-3, here is a table of early BCMA based therapies (combination BCMA (Tec-Dara, Belnrep triplet) and Cilta Cel #ASH25 #mmsm @ASH_hematology Efficacy summary
Pregnancy Management in CML 🤰🧬 — By Dr. Mansour Alfayez 1️⃣ Stop ALL TKIs immediately once pregnancy test is positive. 2️⃣ No treatment unless truly necessary until 13–15 weeks. 3️⃣ After placental formation → • IFN-α safest throughout pregnancy 💉 • Imatinib/Nilotinib may be…
9 Breast Ca studies that we touched on with @VKaklamani for #ESMO25: ✅ #monarchE & #NATALEE ✅ #VIKTORIA1 ✅ #evERA ✅ #DESTINYBreast: 05/09/11 ✅ #ASCENT03 ✅ #TropionBreast02 #OncTwitter #MedTwitter @OncUpdates @myESMO @OncoAlert
Breast Ca Highlights from #ESMO25 w/ @VKaklamani! ✅ #monarchE & #NATALEE ✅ #VIKTORIA1 ✅ #evERA ✅ #DESTINYBreast: 05/09/11 ✅ #ASCENT03 ✅ #TropionBreast02 Full Discussion: - oncbrothers.com/esmo-breast-20… - Also on “Oncology Brothers” podcast #OncTwitter #bcsm
🫁 #MARIPOSA & #FLAURA2 🫁 #lungcancer #nsclc #egfr #LCSM 🌟 Summary of “ indirect “ clinical trials data. 🫁 Clinical data of poorer prognostic factor 🫁
⚡️ Burkitt Leukemia (BLL) – High-Yield Hematology Board Review ⚡️ (Adult focus • aggressive B-cell leukemia/lymphoma variant of BL) ⸻ 🧬 Definition • Leukemic phase of Burkitt Lymphoma with BM blasts ≥20% • MYC-driven high-grade B-cell malignancy • Ki-67 >95% 🔥 extremely…
Plerixafor = magic! We use it to help collect stem cells for BMT! Plerixafor binds CXCR4 receptor on HSCs and 🚫 interaction between CXCR4 and its ligand, CXCL12. CXCL12 tethers HSCs to bone marrow niche 🚫 its interaction with CXCR4 releases HSCs into the circulation!
Recent trials for transplant ineligible newly Dx myeloma! My summary Addition of anti-C38 MAB (dara/isa) prolongs PFS, deepens MRD- vs RVd More toxicity (infections,neutropenia) BENEFIT trial addition of Velcade marginal benefit,doubles neuropathy DRd still a fine regimen to use
HER eBC management is improving survival but more complex. Here is a proposed algorithm with new advances post @myESMO #ESMO25 What do you think? What would you change? @matteolambe @PTarantinoMD @E_de_Azambuja @stolaney1 @Rodrosb @ElisaAgostinett @ErikaHamilton9 @hoperugo
This! Trop2 ADCs should be considered the new standard of care in 1L mTNBC. In the post Keynote 522 era, using the Keynote 355 data makes no sense. These patients have already seen those drugs. Keynote 355 is really obsolete at this point. #ESMO25 #TNBC
Paradigm Shift in 1L TNBC We may be witnessing the end of chemotherapy’s monopoly in PD-L1–negative metastatic TNBC. Dato-DXd delivers the first OS benefit in this setting. SG shows a robust PFS advantage and prolonged DOR ≈ 12 mo. Next frontier → sequencing & chemo-free…
Anaplastic large cell lymphoma represents many distinct clinical entities. This slide summarizes up nicely ALK+ = BV-CHP x 6 ALK- = BV-CHP x 6 +/- ASCT Breast implant ALCL = Remove implant Primary cutaneous ALCL = radiate or resect, more advanced then MTX or BV
This is the treatment algorithm for reference during our discussion on Chronic Myeloid Leukemia with @GCC_Cortes #OncTwitter #MedTwitter #HemeTwitter @OncUpdates
Treatment Algorithm: the current Rx landscape of CML with @GCC_Cortes ✅ Work-up ✅ Rx Options/Sequencing ✅ Monitoring CML & NGS ✅ AEs & Dose optimization Full discussion - oncbrothers.com/cml-algo-2025 - Also on “Oncology Brothers” podcast #MedTwitter #OncTwitter @OncUpdates
🧵 Hodgkin Lymphoma (HL) in Pregnancy – Full Review with Board Pearls, MCQs & OSCE Scenarios 🤰🧬 ⸻ 🔹 Epidemiology & Background 🌸 HL is the most common hematologic malignancy in pregnancy (≈1 in 6,000). 🧫 Most cases = early-stage, nodular sclerosis HL in young women. 💡…
Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial ascopubs.org/doi/abs/10.120… In a multicenter, single-arm phase II trial, the bispecific antibody-drug conjugate BL-B01D1—targeting EGFR and HER3 and…
🧠 CNS Lymphoma (PCNSL & SCNSL) — full review 🧾 Basics •PCNSL = DLBCL confined to brain/eye/CSF/spinal cord; SCNSL = systemic lymphoma with CNS spread. 👀🧬 •Avoid steroids before biopsy if safe → can obscure dx. 🚫💊 🔎 Diagnosis / Work-up •MRI brain ± spine w/…
How I manage MGUS in one Figure 👇
Management of Monoclonal Gammopathy of Undetermined Significance. In low-risk patients who are younger than 50 years of age, bone marrow biopsy and imaging may be considered a baseline evaluation, given the anticipated life expectancy. Learn more: nej.md/473uOsj
In our recent discussion on Venous Thromboembolism, we had a chance to touch on when to consider hypercoagulable work-up (and it's significance 👇👇)! Risk of VTE based on: Factor V Leiden, AT-III, PTG, and Protein C&S! #HemeTwitter #OncTwitter #MedTwitter @OncUpdates
In our “Challenging Cases” discussion w/ @JenVaughnMD @fluorecenteazul we touch on: ✅ Provoked/Unprovoked VTE ✅ Cancer associated VTE ✅ APLS Full discussion: ⭐️ oncbrothers.com/vte-2025 ⭐️ Also on the “Oncology Brothers” podcast #HemeTwitter #OncTwitter #MedEd
If you struggle with Head & Neck SCC — HPV+ vs HPV–? When to offer induction chemo? Surgery vs definitive CRT? This high-yield algorithm breaks it down for boards & practice. #OncTwitter
🧵 von Willebrand disease: 12 high-yield pearls for the boards Common but complex. Here is what hematologists need to remember for diagnosis, subtyping, and management. #HemeBoards #VWD #HemeTwitter #MedTwitter 👇 @isth @ASH_hematology @HemOncFellows @EHA_Hematology
United States الاتجاهات
- 1. Martinelli 60,4 B posts
- 2. Jonathan Ross 56,9 B posts
- 3. JD Vance 257 B posts
- 4. Renee 1,34 Mn posts
- 5. Arsenal 371 B posts
- 6. Liverpool 206 B posts
- 7. Bradley 37,1 B posts
- 8. 17 Republicans 5.998 posts
- 9. #ARSLIV 32,5 B posts
- 10. Gyokeres 30,8 B posts
- 11. Fetty Wap 4.047 posts
- 12. Lviv 12,6 B posts
- 13. DISABLE WLFI COMMENTS N/A
- 14. Charlie Kirk 209 B posts
- 15. Oreshnik 17,4 B posts
- 16. Arteta 43,1 B posts
- 17. Frimpong 11 B posts
- 18. McDonalds 22,9 B posts
- 19. McDaniel 44,3 B posts
- 20. Josh Hawley 20,8 B posts
قد يعجبك
-
د.رضا بخش dr.bakhsh
@bakhsh_reda -
Mohamed Aseafan
@MAseafan -
د. كنعان الشمري Kanan Alshammari, MD
@Dr_Kanaan07 -
Mohamed Kharfan-Dabaja, MD, MBA
@MKD_BMT -
Somedeb Ball
@drsomedeb -
Nadim Malibary نديم مليباري
@NadimMalibary -
Dr. Abdurahman Alloghbi د.عبدالرحمن اللغبي
@AAlloghbi -
Waddah Arafat
@WaddahArafat -
غالية جادكريم
@galiajadkarim -
Arthi Sridhar
@ASridharMD -
محمد الخليفة 🇸🇩
@butcher186 -
Rami Mahfouz MD,MPH
@RamiMahfouzMD -
Samaher Ashram د.سماهر أشرم
@DrSamaherAshram -
Dr jean elcheikh
@elcheikhjean -
Tamer Refaat, MD PhD MSCI
@TamerRefaatMD
Something went wrong.
Something went wrong.